Global Cancer Supportive Care Drugs Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027
“Global Cancer Supportive Care Drugs Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2027” is a recent report generated by MarketResearch.biz, which offers in-depth insights, revenue details, and other vital information regarding the global cancer supportive care drugs market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global cancer supportive care drugs market report has been segmented on the basis of therapeutic class and region.
Supportive cancer drugs are also called protective cancer drugs or oncology supportive drugs. They are used to lessen the harmful side effects associated with cancer treatment by protecting certain cells or organs of body. Supportive cancer care is form of care that focuses on relieving symptoms caused by serious illnesses of cancer diseases.
Key factors expected to drive growth of the global cancer supportive care drugs market are rising prevelance of cancer diseases and number of side-effects associated with cancer treatment, across the globe. In addition, growing geriatric population, rising consumption of biosimilar drugs, increasing healthcare expenditure, rising awareness regarding anti-cancer drug, and government and several other organizations initiatives for spreading and formulating awareness program are some other factors expected to drive growth of the global cancer supportive care drugs market. Furthermore, increased purchasing power of urban population in developing countries, government reimbursement programs, rinsing prevelance of lungs and breast cancer, and increasing need to manage them effectively are some other factors expected to drive growth of the target market over the forecasted period. However, strict regulation and side effects associated with cancer drugs affect the quality of life of the patient are some of the factors expected to hamper growth of the global cancer supportive care drugs market to a certain extent over the forecast period.
Established players are focusing on partnering with various local players emerging economies of Asia Pacific and by increasing their investments in R&D activities in this region. In addition, prominent players are focusing on getting the approval for the new drugs in order to expand its market share, are key trend observed in the global cancer supportive care drugs market, currently. In September 2018, for instance Verastem, Inc. which is the US-based biopharmaceutical company received an US FDA approval for COPIKTRA (duvelisib) capsules – used in adult patients for the treatment of relapsed or refractory chronic lymphocytic leukemia.
The market in North America is expected to dominate in the global cancer supportive care drugs market. This is primarily attributed to rising incidence of cancer and high adoption of new technology countries in the region. According to the National Cancer Institute (NIH) in 2017, there were approximately 1.5 Mn new cases of cancer in US. The market in Asia Pacific is expected to be an emerging market for the global cancer supportive care drugs market, and is expected to register highest CAGR over the forecast period. This is attributed to rising healthcare expenditure and growing geriatric population in countries in the region. Moreover, the markets in Europe, Latin America and Middle East & Africa are expected to register significant higher revenue growth in the global cancer supportive care drugs market over the forecast period.
GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SEGMENTATION:
Segmentation by therapeutic class:
- G-CSFs (Granulocyte colony stimulating factor)
- ESAs (erythropoiesis-stimulating agents)
- NSAIDs (Nonsteroidal anti-inflammatory drug)
- Other Drug Classes (include antineoplastic antibiotics, neutropenia, etc.)
Segmentation by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2017 Estimated Year 2018 Forecast Period 2018–2028 Revenue in US$
- Amgen Inc.
- Helsinn Healthcare SA
- Heron Therapeutics, Inc.
- Johnson & Johnson
- Merck & Company, Inc.
- Novartis AG (Sandoz)
- Hoffmann-La Roche AG
- Tesaro Inc.
- Baxter International Inc.
- Fagron Group BV.
- Teva Pharmaceuticals Industries Ltd.
- APR Applied Pharma Science Research S.A.
- Acacia Pharma Ltd.
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!